C Mattsson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

C Mattsson

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Cardiovascular Research|December 1, 1995

Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysisL Y Chen, W W Nichols, C Mattsson, et al.

Journal of the American College of Cardiology|July 1, 1992

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activatorF A Nicolini, W W Nichols, J L Mehta, et al.

Thrombosis and Haemostasis|February 12, 1998

Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymesD Gustafsson, T Antonsson, R Bylund, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Cardiovascular Research|December 1, 1995

Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysisL Y Chen, W W Nichols, C Mattsson, et al.

Journal of the American College of Cardiology|July 1, 1992

Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activatorF A Nicolini, W W Nichols, J L Mehta, et al.

Thrombosis and Haemostasis|February 12, 1998

Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymesD Gustafsson, T Antonsson, R Bylund, et al.

Pageof 5